Parallel Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.47M | Buy |
5,522
+333
| +6% | +$155K | 0.04% | 262 |
|
|
2025
Q4 | $2.35M | Buy |
5,189
+134
| +3% | +$57.8K | 0.04% | 256 |
|
|
2025
Q3 | $1.98M | Sell |
5,055
-211
| -4% | -$88.2K | 0.04% | 286 |
|
|
2025
Q2 | $2.34M | Sell |
5,266
-184
| -3% | -$84.8K | 0.05% | 244 |
|
|
2025
Q1 | $2.64M | Sell |
5,450
-1,885
| -26% | -$878K | 0.06% | 210 |
|
|
2024
Q4 | $2.95M | Buy |
7,335
+143
| +2% | +$66.3K | 0.07% | 203 |
|
|
2024
Q3 | $3.34M | Buy |
7,192
+820
| +13% | +$394K | 0.08% | 191 |
|
|
2024
Q2 | $2.99M | Buy |
6,372
+863
| +16% | +$375K | 0.08% | 189 |
|
|
2024
Q1 | $2.3M | Buy |
5,509
+733
| +15% | +$310K | 0.06% | 210 |
|
|
2023
Q4 | $1.94M | Buy |
4,776
+1,309
| +38% | +$484K | 0.06% | 208 |
|
|
2023
Q3 | $1.21M | Buy |
3,467
+242
| +8% | +$84.6K | 0.04% | 280 |
|
|
2023
Q2 | $1.13M | Buy |
3,225
+177
| +6% | +$59.6K | 0.04% | 298 |
|
|
2023
Q1 | $960K | Buy |
3,048
+843
| +38% | +$253K | 0.03% | 319 |
|
|
2022
Q4 | $637K | Buy |
2,205
+22
| +1% | +$6.71K | 0.03% | 347 |
|
|
2022
Q3 | $632K | Buy |
2,183
+159
| +8% | +$45.7K | 0.03% | 333 |
|
|
2022
Q2 | $570K | Buy |
2,024
+71
| +4% | +$19K | 0.03% | 359 |
|
|
2022
Q1 | $501K | Buy |
1,953
+101
| +5% | +$24K | 0.02% | 428 |
|
|
2021
Q4 | $407K | Buy |
1,852
+400
| +28% | +$77.8K | 0.02% | 511 |
|
|
2021
Q3 | $263K | Buy |
1,452
+115
| +9% | +$22.5K | 0.01% | 616 |
|
|
2021
Q2 | $270K | Buy |
1,337
+69
| +5% | +$14.4K | 0.01% | 571 |
|
|
2021
Q1 | $272K | Buy |
1,268
+22
| +2% | +$4.83K | 0.01% | 534 |
|
|
2020
Q4 | $294K | Sell |
1,246
-131
| -10% | -$30.1K | 0.02% | 471 |
|
|
2020
Q3 | $375K | Sell |
1,377
-55
| -4% | -$15.2K | 0.02% | 370 |
|
|
2020
Q2 | $415K | Buy |
1,432
+156
| +12% | +$42.3K | 0.03% | 337 |
|
|
2020
Q1 | $303K | Buy |
1,276
+149
| +13% | +$34.2K | 0.02% | 349 |
|
|
2019
Q4 | $247K | Buy |
1,127
+48
| +4% | +$9.71K | 0.02% | 438 |
|
|
2019
Q3 | $183K | Buy |
1,079
+143
| +15% | +$25.3K | 0.02% | 503 |
|
|
2019
Q2 | $172K | Sell |
936
-63
| -6% | -$11K | 0.02% | 484 |
|
|
2019
Q1 | $184K | Sell |
999
-92
| -8% | -$17K | 0.02% | 434 |
|
|
2018
Q4 | $180K | Buy |
1,091
+60
| +6% | +$10.4K | 0.03% | 382 |
|
|
2018
Q3 | $199K | Buy |
1,031
+10
| +1% | +$1.78K | 0.02% | 384 |
|
|
2018
Q2 | $173K | Buy |
1,021
+178
| +21% | +$27.6K | 0.02% | 392 |
|
|
2018
Q1 | $137K | Buy |
843
+29
| +4% | +$4.74K | 0.02% | 415 |
|
|
2017
Q4 | $122K | Sell |
814
-16
| -2% | -$2.37K | 0.02% | 431 |
|
|
2017
Q3 | $123K | Buy |
830
+63
| +8% | +$9.48K | 0.02% | 426 |
|
|
2017
Q2 | $116K | Sell |
767
-4
| -0.5% | -$482 | 0.02% | 435 |
|
|
2017
Q1 | $92K | Buy |
771
+177
| +30% | +$15.6K | 0.02% | 475 |
|
|
2016
Q4 | $44K | Buy |
+594
| New | +$48.3K | 0.01% | 629 |
|
Other funds holding VRTX
VCM
VPM
Parallel Advisors's VRTX Position: Q1 2026 in Review
Parallel Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 6.4% in Q1 2026, buying an estimated $155K and bringing the position to 5,522 shares worth $2.47M. The position accounts for 0.04% of the portfolio, ranked #262.
Parallel Advisors first reported a position in VRTX in Q4 2016 and has held it in 38 quarters since. The position peaked at $3.34M in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Parallel Advisors held 5,522 shares of Vertex Pharmaceuticals worth $2.47M as of Q1 2026.
- Parallel Advisors bought 333 Vertex Pharmaceuticals shares in Q1 2026, an estimated $155K.
- Vertex Pharmaceuticals made up 0.04% of Parallel Advisors's portfolio in Q1 2026, its #262 holding.
- Parallel Advisors first reported a position in Vertex Pharmaceuticals in Q4 2016 and has held it in 38 quarters since.
- Parallel Advisors's Vertex Pharmaceuticals position peaked at $3.34M in Q3 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.